CEO & Co-founder
Leveraging 35+ years of microbiology expertise
to revolutionize water testing technology
BLUEPHAGE S.L. is a biotechnology company specializing in environmental testing solutions and launched as a spinoff company in 2016 from the University of Barcelona, Spain. Using a patent-protected accelerated coliphage indicator test, our microbiological water quality testing products detect bacteriophages as indicators of viruses that cause serious waterborne diseases. Our product pipeline will offer the fastest and easiest to use bacteriophage detection method currently available on the market for environmental testing of water.
BLUEPHAGE’s team of world renowned experts in basic and applied microbiology and virology in water testing methods tap into 35+ years of knowledge and know-how developed at the University of Barcelona within the MARS research group (Water Microbiology Related to Health).
Testing for coliphages will become a new parameter
for routine water evaluation
Bacterial indicators fail to detect a broad range of enteric viruses in water samples and involve lengthy culture-based methods requiring extensive material prep time, skilled staff and special equipment. On top of these shortcoming, current testing for bacteriophages (specifically coliphages) using the EPA and ISO methods, takes nearly 48 hours to perform including material prep time. Shortcomings in traditional faecal indicator bacteria (FIB) testing methods has led to new state-of-the-art use of coliphages as more accurate viral indicators.
BLUEPHAGE’s rapid-steps lab kits include patent protected CRMs to monitor water quality for all types of water, food and biosolids. Easy to use, offering high sensitivity and rapid results under 5 hours, our lab kits provide the most reliable viral indicators for water safety monitoring.
A New Paradigm for Water Testing
CEO and Business Developer is a geologist (UB) with master’s degrees in Water Geology (UPC) and General Management (PDG- EADA) with more than 16 years’ experience working in water sector. Since 2002 he has been the Managing Director of cuadll.org. In parallel, between 2007 and 2013, he was an entrepreneur and CEO of FITA10: a water, geology and natural environment consultancy.
His work is focused on development and application in the environment of selective and specific methods for the detection of bacterial species, mainly health-related water microbiology. He also works on the epidemiology and ecology of different bacterial populations. He has participated in nine EU projects since 1989 as a scientist (4), the chief scientist (4) and as the coordinator of the MST project TOFPSW.
Chairman of MARS and has more than 30 years’ experience in basic and applied water microbiology. He has participated in eight EU projects since 1991 with a significant participation in assessing the potential use of phages as model microorganisms and in developing methods for the detection of human viruses and protozoa in sludge and water samples. He was the secretary and a member of the ECOPROGES SL board from 1990 to 2000, a University of Barcelona spin-off.
Joan Jofre has more than 35 years’ experience in microbiological research. He has participated in eight EU projects since 1989. He has worked on developing methods for studying the behavior outside the gut of human enteric viruses and on developing methods for detection, characterization and studying ecology outside the gut of bacteriophages that infect enteric bacteria, mainly on bacteriophages infecting Bacteroides fragilis as well as other coliphages.
Native New Yorker, who now calls Spain her second home, Susan is an experienced, international professional with strong business development and US market entry expertise for companies in the life sciences and healthcare sectors. Susan is an international “connector” and our business translator able to distill complex technology or concepts and define into tangible business and customer needs. Susan brings value in business model innovation to take BLUEPHAGE business ideas to the next level with a high tolerance for ambiguity and risk. She has advised multiple startups and is our door opener for business between USA and Spain. A licensed lawyer and graduate of the Stanford affiliated Biodesign program D∙Health Barcelona.
Jaume Amat is an entrepreneur and has a long track record in start-ups having been directly involved in creating a number of companies in the BioTech and BioMed sector. He is the founder and CEO of Specific Pig SL and Rob Surgical Systems SL. As well as the founder and a board member of Manremyc SL, Aniling SL, and Good Gut SL; and a board member of Vcn Biosciences SL. Furthermore, he was the founder and CEO of Archivel Farma. He graduated in Telecommunications Engineering (URL BCN) has an MBA (IESE Business School) and qualifications in Social Leadership (ESADE), Motivation and Leadership (University of Auckland Business School) and Strategic Negotiations (UPF BCN).
The kits can be in the format of Absence/Presence or in the MPN (most probable number) format.
BP10 kit is a product that allows analysis of somatic coliphages in 4 hours.
BP12 kit is a product that allows analysis of somatic and F-specific coliphages at same time.
BP14 kit is a product that allows analysis of F-specific coliphages.